FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies
FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies
The U.S. Food and Drug Administration today announced the availability of the first draft guidance for industry on Risk Evaluation and Mitigation Strategies or REMS, which are required for certain drugs or biologics.